Integer (NYSE:ITGR) PT Lowered to $4.29 at Argus

Integer (NYSE:ITGR) had its price objective cut by research analysts at Argus from $90.00 to $4.29 in a report released on Wednesday, June 5th, The Fly reports. The firm currently has an “average” rating on the medical equipment provider’s stock. Argus’ price objective would suggest a potential downside of 94.89% from the company’s current price. The analysts noted that the move was a valuation call.

A number of other research firms have also recently commented on ITGR. Zacks Investment Research upgraded shares of Integer from a “hold” rating to a “strong-buy” rating and set a $101.00 price target on the stock in a report on Tuesday, February 26th. Royal Bank of Canada raised their target price on shares of Integer from $84.00 to $92.00 and gave the stock a “sector perform” rating in a report on Monday, February 25th. Finally, ValuEngine downgraded shares of Integer from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $74.66.

NYSE:ITGR traded down $1.02 during trading hours on Wednesday, hitting $83.92. 578,100 shares of the company were exchanged, compared to its average volume of 246,922. The business’s fifty day moving average is $75.26. The company has a market cap of $2.77 billion, a PE ratio of 22.08 and a beta of 0.84. The company has a quick ratio of 1.49, a current ratio of 2.55 and a debt-to-equity ratio of 0.84. Integer has a one year low of $63.50 and a one year high of $92.61.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.00 EPS for the quarter, beating the consensus estimate of $0.80 by $0.20. Integer had a net margin of 14.67% and a return on equity of 13.37%. The firm had revenue of $314.70 million during the quarter, compared to the consensus estimate of $302.29 million. During the same period in the prior year, the firm posted $0.61 earnings per share. The company’s quarterly revenue was up 7.6% compared to the same quarter last year. On average, research analysts anticipate that Integer will post 4.3 EPS for the current year.

In other news, Director James F. Hinrichs acquired 3,750 shares of Integer stock in a transaction that occurred on Thursday, May 23rd. The stock was purchased at an average price of $68.47 per share, for a total transaction of $256,762.50. Following the purchase, the director now directly owns 6,549 shares in the company, valued at approximately $448,410.03. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.24% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Optimum Investment Advisors acquired a new stake in Integer during the first quarter worth about $30,000. Robeco Institutional Asset Management B.V. acquired a new position in shares of Integer in the 1st quarter valued at $40,000. Financial Gravity Wealth Inc. purchased a new position in Integer in the 1st quarter valued at $45,000. Financial Gravity Companies Inc. purchased a new position in Integer in the 4th quarter valued at $49,000. Finally, PNC Financial Services Group Inc. boosted its position in shares of Integer by 15.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,065 shares of the medical equipment provider’s stock worth $81,000 after purchasing an additional 145 shares in the last quarter. 96.00% of the stock is currently owned by institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide. It operates in two segments, Medical and Non-Medical. The company offers products for vascular, cardiac surgery, and structural heart diseases; peripheral vascular, neurovascular, urology, and oncology products; and electrophysiology, infusion therapy, and hemodialysis products.

Featured Article: Portfolio Manager

The Fly

Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with's FREE daily email newsletter.